Best Stocks To Buy Now April 29, 2022

The S&P500 trades at $4,287 while the Dow Jones today trades at $33,469. The Nasdaq reaches $162.5 with bearish feelings toward Amazon after yesterday’s poor earnings (AMZN stock forecast for the next 12 months is now at less than $4k).

We have listed below the best stocks to buy now

Anheuser-Busch InBev (NYSE:BUD)

Deutsche Bank Research has set a price target of EUR64.00 for Anheuser-Busch InBev SA/NV. (NYSE:BUD).

JPMorgan Chase & Co. has set a price target for Anheuser-Busch InBev SA?NV (NYSE:BUD) at EUR55.00 ($59.14). According to a Barclays research, Anheuser-Busch SA/NV’s price target was EUR72.00 ($77.42) according to a Wednesday, April 20 Barclays research. IN A RESEARCH NOTE, Sanford C. Bernstein released a target price for Anheuser-Busch InBev SA/NV at EUR67.00 ($72.04).

Six investment experts rated the stock as a buy, while four others rated it as a hold and four as solid buys. MarketBeat.com currently rates the stock as a Buy, while four experts rate it a Hold. The consensus price target for the stock is EUR65.22 ($70.12).

The company’s years to date low and high are EUR82.03 ($88.20) and EUR110.10 (118.39), respectively. Anadolu Efes (Turkish brewer) is interested in buying AB InBev’s non-controlling stake in the AB InBev Efes joint enterprise in 2022 (April 22). AB InBev announced that it plans to sell its non-controlling stake in the AB InBev Efes venture. AB InBev also requested that Russia’s license to produce and sell Bud be suspended as part of any possible deal. 

AB InBev, a non-controlling shareholder in the joint venture, has already stated that it will forfeit all financial rewards. In addition, AB InBev will report a non-cash impairment charge of over $1.1 billion in its first-quarter results. It is de-recognizing all of its investments in AB InBev Efes.

Robert Half International (NYSE:RHI)

CL King equity experts raised their price target for Robert Half International (NYSE:RHI) on Wednesday from $128.00 per stock to $132.00. CL King estimates that the stock could rise by 20% from its current price.

The opening price of shares in Robert Half International was $109.36 this week. Over the past two hundred days, the company’s moving average has been $113.58. That is the same price as its 50-day average. The company’s market value is at $12.12 billion. P/E is 20.44, while the PE/G ratio is 2.75. Furthermore, the beta is 1.44. Beta is at 1.44.

It was Tuesday, April 26th, when Robert Half International (NYSE.RHI – Get Rating) reported its most recent financial results. In fact, analysts had predicted that EPS would be $1.46, but it was $1.52. Analysts expected revenues of $1.80 billion for the third quarter. In actuality, the company made $1.81 billion in profit.

A 29.8% year-over-year increase in revenue was reported by the corporation in the third quarter. During the same period the previous year, the company made a profit of $0.98 per share. Expected profits per share for Robert Half International for the current year are 6.2.

Idexx Laboratories, Inc.(NASDAQ:IDXX)

Wednesday will see IDEXX Laboratories’ (NASDAQ:IDXX) quarterly earnings announcement.

Wednesday, May 4, IDEXx Laboratories (NASDAQ:IDXX) will release its quarterly results data. Analysts predict that IDEXX Laboratories will report third-quarter profits of $2.26 per share. In addition, IDEXX Laboratories anticipates earning between $9.27 and $9.59 per share. If you would like to join the conference call, please click this link.

IDXX shares opened at $455.56 on Wednesday. This company is valued at $38.38 million. One hundred and one. In the last year, IDEXX Laboratories experienced a low of $455.34 and a high of $706.95. The company has 0.90 short-term liquid assets and 1.25 current assets. The debt-to-equity ratio is 12 percent.

Monolith Advisors acquired IDEXX Laboratories stock for $66,000 in the fourth quarter. In addition, KB Financial Partners LLC acquired shares in IDEXX Laboratories, Inc this quarter. It was $72,000 after everything was said and done. Investments in IDEXX Laboratories totaled roughly $212,000 in the fourth quarter of 2013. Institutions hold 83.80% of the company’s stock.

The analysts gave the company an “overweight” rating and a target price of $650.00. Two stock analysts rate the stock as a “hold,” and six rate it as an “excellent buy.” According to MarketBeat.com data, the company has a consensus target price of $702.40 and a “Buy” average rating.

Gilead Sciences(NASDAQ:GILD)

There have been many changes to broker recommendations and price goals for Gilead Sciences shares (NASDAQ:GILD).

Royal Bank of Canada analysts raised their price estimate for Gilead Sciences to $77.00 on 12/4/2022. The stock currently has the status of “Outperform.”

Morgan Stanley analysts reduced Gilead Sciences’ price objective to $63.000 from $69.00 as of April 12, 2022. In addition, they have given the stock a new “equal weight” rating.

Piper Sandler analysts raised their price target for Gilead Sciences to $72.00 as of April 12, 2022.

Piper Sandler analysts have decreased the price estimate of Gilead Sciences from $77.00 to $71.00 in 2022-04-22They have now downgraded Gilead Sciences’ stock to “neutral.”

StockNews.com analysts in 2022-03-30 are following Gilead Sciences. They gave the stock a recommendation of “buy.”

On March 10, 2022, Analysts at Barclays PLC reduced Gilead Sciences’ price estimate from $63.00 – $56.00. As a result, the stock has been downgraded from an “underweight” rating.

On March 8, 2022. BMO Capital Markets added analysts to its coverage on Gilead Sciences. They rate the stock “Hold” and have a $65.00 price target.

Royal Bank of Canada analysts reduced Gilead Sciences’ estimated price from $85.00 to $77.00 on March 7, 2022. The stock currently has the status of “Outperform.”

Monday’s trading saw shares of GILD stock fall by $0.50 to $61.75, compared with the company’s average volume (10630,844). The 52-week low for Gilead Sciences, Inc. shares is $57.19, while the 52-week high closes at $74.12.

Shares of GILD stock are currently valued at $77.43billion, with a P/E of 12.53, a price/earnings/G of 0.46, and a beta of 0.40. The firm’s current ratio is 1.27, and its quick ratio 1.13. Meanwhile, the debt-to-equity ratio for the company is 1.24. The simple moving averages for the 50- and 200-day periods are 60.52 and $65.88.

A quarterly dividend was paid on March 30, as previously stated. Shareholders who held a record date of Tuesday, March 15, received a $0.73 per share. Shareholders who had a record date of Tuesday, March 15, received a $0.73 per share. Gilead Sciences previously paid a $0.71 quarterly distribution, an increase. Gilead Sciences currently has a payout ratio of 59.23%.

On March 11, the company’s EVP Brett A. Pletcher also sold 3,634 shares. A document filed with the Securities and Exchange Commission (SEC) made the sale public. The transaction was not the only one that occurred on February 1. Executive Vice President Brett Pletcher also sold 14,061 shares. At an average of $68.54, the stock was sold at $963,740.94.

Recent changes in institutional investors’ holdings have seen the stock drop. Joseph P. Lucia & Associates LLC purchased $25,000 worth of Gilead Sciences stock in the first quarter. TFO TDC LLC made a $27,000 new investment in Gilead Sciences in the first quarter. FSB Premier Wealth Management Inc. bought a $28,000 investment into Gilead Sciences in the fourth quarter.

OLD Second National Bank of Aurora grew by 46.3% its stake in Gilead Sciences during the third quarter. OLD Second National Bank of Aurora had 439 shares of stock in the biopharmaceutical firm, valued at $31,000, as of the close of the last quarter. Capital Advisors Ltd. LLC increased its Gilead Sciences holdings by 12.7 percent in the fourth quarter. Capital Advisors Ltd.